Going past the data for temozolomide

J. Lee Villano; Nathalie Letarte; Linda R. Bressler

doi:10.1007/s00280-011-1796-4

Going past the data for temozolomide

J. Lee Villano, Nathalie Letarte, Linda R. Bressler

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

Original language	English
Pages (from-to)	1113-1115
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	69
Issue number	4
DOIs	https://doi.org/10.1007/s00280-011-1796-4
State	Published - Apr 2012

Keywords

Adjuvant therapy
Brain tumor
Glioblastoma
Temozolomide

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-011-1796-4

Cite this

@article{3ca7f1043b734e4bb58a169b18df4e5c,

title = "Going past the data for temozolomide",

abstract = "The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.",

keywords = "Adjuvant therapy, Brain tumor, Glioblastoma, Temozolomide",

author = "Villano, {J. Lee} and Nathalie Letarte and Bressler, {Linda R.}",

year = "2012",

month = apr,

doi = "10.1007/s00280-011-1796-4",

language = "English",

volume = "69",

pages = "1113--1115",

number = "4",

}

TY - JOUR

T1 - Going past the data for temozolomide

AU - Villano, J. Lee

AU - Letarte, Nathalie

AU - Bressler, Linda R.

PY - 2012/4

Y1 - 2012/4

N2 - The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

AB - The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

KW - Adjuvant therapy

KW - Brain tumor

KW - Glioblastoma

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84859803684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859803684&partnerID=8YFLogxK

U2 - 10.1007/s00280-011-1796-4

DO - 10.1007/s00280-011-1796-4

M3 - Comment/debate

C2 - 22147076

AN - SCOPUS:84859803684

VL - 69

SP - 1113

EP - 1115

IS - 4

ER -

Going past the data for temozolomide

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this